MBD1 antibody (C-Term)

Catalog No. ABIN1882100

The Rabbit Polyclonal anti-MBD1 antibody has been validated for WB. It is suitable to detect MBD1 in samples from Human. There is 1 publication available.

Quick Overview for MBD1 antibody (C-Term) (ABIN1882100)

Target: MBD1 (Methyl-CpG Binding Domain Protein 1 (MBD1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MBD1 antibody is un-conjugated

Application: Western Blotting (WB)

Clone: RB2371

Product Details anti-MBD1 Antibody

Binding Specificity: AA 376-405, C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This MBD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 376-405 amino acids from the C-terminal region of human MBD1.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-MBD1 antibody (ABIN1882100)

Auriol, Billard, Magdinier, Dante: "Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus." in: Nucleic acids research, Vol. 33, Issue 13, pp. 4243-54, (2005) (PubMed).

Target Details for MBD1

Target: MBD1 (Methyl-CpG Binding Domain Protein 1 (MBD1))

Alternative Name: MBD1

Background: DNA methylation, or the addition of methyl groups to cytosine bases in the dinucleotide CpG, is imperative to proper development and regulates gene expression. The methylation pattern involves the enzymatic processes of methylation and demethylation. The demethylation enzyme was recently found to be a mammalian protein, which exhibits demethylase activity associated to a methyl-CpG-binding domain (MBD) (1). The enzyme is able to revert methylated cytosine bases to cytosines within the particular dinucleotide sequence mdCpdG by catalyzing the cleaving of the methyl group as methanol. MeCP2 and MBD1 (PCM1) are first found to repress transcription by binding specifically to methylated DNA (2). MBD2 and MBD4 (also known as MED1) were later found to colocalize with foci of heavily methylated satellite DNA and believed to mediate the biological functions of the methylation signal. Surprisingly, MBD3 does not bind methylated DNA both in vivo and in vitro. MBD1, MBD2, MBD3, and MBD4 are found to be expressed in somatic tissues, but the expression of MBD1 and MBD2 is reduced or absent in embryonic stem cells, which are known to be deficient in MeCP1 activity. MBD4 have homology to bacterial base excision repair DNA N-glycosylases/lyases (3). In some microsatellite unstable tumors MBD4 is mutated at an exonic polynucleotide tract (4).

Molecular Weight: 66607

NCBI Accession: NP_001191065, NP_001191066, NP_001191067, NP_001191068, NP_001191069, NP_001191070, NP_001191071, NP_001191072, NP_001191080, NP_002375, NP_056669, NP_056670, NP_056671, NP_056723

UniProt: Q9UIS9